Compare Ascendis Pharma A/S (ASND) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Alliant Energy Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Alliant Energy Corporation trades at $76.4 (market cap $19.73B). The key difference: Ascendis Pharma A/S and Alliant Energy Corporation are close in size by market cap, and Alliant Energy Corporation pays a 2.73% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LNT | |
|---|---|---|
Market Cap | $17.74B | $19.73B |
Sector | Health | Utilities |
52-Week High | $277.18 | $78.03 |
52-Week Low | $163.32 | $61.85 |
Enterprise Value | $18.11B | $31.45B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
LNT trades at $76.40, up 0.92% today, with a bullish technical signal and mixed earnings history including a recent Q1 2026 beat. The company shows steady revenue growth to $4.36B in 2025 and a net margin of 18.58%, supported by a $13.4B investment plan and data center demand. Analysts are split with a 52% buy rating and a $75.67 consensus target, while the stock pays a $0.54 dividend.
Outlook is positive due to strategic investments and sector tailwinds, but risks include rising debt levels and interest rate sensitivity. The stock offers growth and income appeal, though investors should monitor execution on capital expenditures and competitive pressures in the utility space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
